Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.
4:30 PM - 4:45 PM (EST), Monday, February 6, 2023 ・ Palace
Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd (Atom Bioscience) is a privately held, clinical stage, small molecule discovery and development company founded in 2012 in China. Atom Bioscience is focused on discovery and development of best-in-class drugs for inflammatory and metabolic disease. Our current development pipeline includes a phase 2b stage URAT1 inhibitor for chronic gout and hyperuricemia, an XO inhibitor for treatment of chronic gout and a product for treatment of acute gout program in pre-IND stage.
To date, Atom Bioscience has raised over $87 million USD including a $47 million Series C closing in Dec. 2021 from investors including KAITAI Capital, Kingray Capital, ShenZen GTJA Group, YouChoose Capital, Ch-gemstone Capital, Livzon Pharmaceutical Group, Sequoia Capital (China) and Fortune Capital
To date, Atom Bioscience has raised over $87 million USD including a $47 million Series C closing in Dec. 2021 from investors including KAITAI Capital, Kingray Capital, ShenZen GTJA Group, YouChoose Capital, Ch-gemstone Capital, Livzon Pharmaceutical Group, Sequoia Capital (China) and Fortune Capital
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
China
Year Founded:
2012
Main Therapeutic Focus:
Metabolic Diseases
Lead Product in Development:
ABP-671 (URAT1 Inhibitor)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
